Intestinal type scoring model for undifferentiated spondyloarthritis and construction method and application thereof

By constructing an intestinal type scoring model and using Dirichlet multinomial mixed unsupervised clustering and LEfSe to screen biomarkers, the gut microbiota characteristics of uSpA samples were identified. This solved the problem of unclear pathogenesis of uSpA, and enabled effective classification and clinical feature analysis of uSpA, providing theoretical support for its diagnosis and treatment.

CN115662505BActive Publication Date: 2026-02-06SHANXI MEDICAL UNIV
2 Cites 0 Cited by

Patent Information

Application Number
CN202211111708.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-13
Publication Date
2026-02-06
Estimated Expiration
2042-09-13

AI Technical Summary

Technical Problem

The pathogenesis of undifferentiated spondyloarthritis (uSpA) is unclear, and current technologies lack effective diagnostic and treatment methods.

Method used

A gut type scoring model for undifferentiated spondyloarthritis was constructed. By mining the characteristics of gut microbiota in uSpA samples, Dirichlet multinomial mixed unsupervised clustering and LEfSe were used to screen gut microbial classification markers. Principal component analysis was combined to extract gut type feature scores, which were divided into E1 type and E2 type, and the dominant microbiota of each type were identified.

Benefits of technology

This study effectively distinguishes between two intestinal types in uSpA samples, reveals the association between intestinal type and dietary habits, provides a deeper understanding of uSpA disease, and offers a theoretical basis for its diagnosis and treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application discloses an intestinal type scoring model for undifferentiated spondyloarthropathy and a construction method and application thereof, and belongs to the technical field of medicines.The 16s rRNA intestinal flora amplicon of 100 uSpA subjects is detected by using high-throughput second-generation sequencing.The intestinal type classification is explored, the intestinal type scoring is constructed, and the clinical characteristics of different intestinal types are researched.The research mainly includes the following four parts:(1) collecting the stool samples and peripheral blood of the uSpA subjects, and detecting the peripheral lymphocytes and cytokines by using flow cytometry (FCM) and CBA method;(2) performing intestinal flora 16s sequencing by using the lllumina high-throughput sequencing technology;(3) analyzing the 16s sequencing data by using the QIIME2 platform;(4) describing the variability of the microbiome data by using the Dirichlet multinomial mixture unsupervised clustering, classifying the intestinal flora of the uSpA, and mining the characteristics of the intestinal flora of the subjects.
Need to check novelty before this filing date? Find Prior Art